Oruka Therapeutics (NASDAQ:ORKA – Get Free Report) is one of 39 public companies in the “Diagnostic substances” industry, but how does it contrast to its rivals? We will compare Oruka Therapeutics to related businesses based on the strength of its institutional ownership, analyst recommendations, earnings, valuation, risk, dividends and profitability.
Profitability
This table compares Oruka Therapeutics and its rivals’ net margins, return on equity and return on assets.
Net Margins | Return on Equity | Return on Assets | |
Oruka Therapeutics | N/A | -20.18% | -19.51% |
Oruka Therapeutics Competitors | -1,887.59% | -41.66% | -26.54% |
Valuation and Earnings
This table compares Oruka Therapeutics and its rivals top-line revenue, earnings per share (EPS) and valuation.
Gross Revenue | Net Income | Price/Earnings Ratio | |
Oruka Therapeutics | N/A | -$5.34 million | -4.53 |
Oruka Therapeutics Competitors | $550.52 million | $6.13 million | -106.30 |
Volatility & Risk
Oruka Therapeutics has a beta of 0.87, indicating that its share price is 13% less volatile than the S&P 500. Comparatively, Oruka Therapeutics’ rivals have a beta of 1.29, indicating that their average share price is 29% more volatile than the S&P 500.
Analyst Recommendations
This is a summary of recent ratings for Oruka Therapeutics and its rivals, as reported by MarketBeat.
Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
Oruka Therapeutics | 0 | 0 | 6 | 2 | 3.25 |
Oruka Therapeutics Competitors | 864 | 811 | 1351 | 23 | 2.17 |
Oruka Therapeutics currently has a consensus price target of $43.17, suggesting a potential upside of 58.76%. As a group, “Diagnostic substances” companies have a potential upside of 46.86%. Given Oruka Therapeutics’ stronger consensus rating and higher probable upside, research analysts clearly believe Oruka Therapeutics is more favorable than its rivals.
Insider & Institutional Ownership
56.4% of Oruka Therapeutics shares are held by institutional investors. Comparatively, 44.7% of shares of all “Diagnostic substances” companies are held by institutional investors. 22.7% of Oruka Therapeutics shares are held by company insiders. Comparatively, 12.6% of shares of all “Diagnostic substances” companies are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Oruka Therapeutics beats its rivals on 10 of the 13 factors compared.
Oruka Therapeutics Company Profile
ARCA biopharma, Inc., a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products. The Company’s business focus combines expertise in cardiovascular pathophysiology, molecular genetics, clinical development and product commercialization. It is currently developing Gencaro (bucindolol hydrochloride), a cardiovascular drug for the treatment of chronic heart failure. The company is based in Broomfield, Colorado.
Receive News & Ratings for Oruka Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oruka Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.